Zometapine
Zometapine is an atypical antipsychotic drug that was developed in the late 20th century. It is classified as a dibenzothiazepine derivative and is closely related to other antipsychotic drugs such as clozapine and olanzapine.
History[edit | edit source]
Zometapine was first synthesized in the 1970s by the pharmaceutical company Novartis. It was initially developed as a potential treatment for schizophrenia and other psychotic disorders. However, despite showing promise in early clinical trials, the drug was never marketed and is not currently approved for use in any country.
Pharmacology[edit | edit source]
Zometapine acts primarily as a dopamine antagonist, blocking the action of the neurotransmitter dopamine in the brain. It also has significant serotonin antagonist activity, which may contribute to its antipsychotic effects. In addition, zometapine has been found to have anticholinergic properties, which can cause side effects such as dry mouth and blurred vision.
Clinical Use[edit | edit source]
While zometapine is not currently approved for use in any country, it has been studied in clinical trials for the treatment of schizophrenia and other psychotic disorders. These studies have suggested that zometapine may be effective in reducing the symptoms of these conditions, although further research is needed to confirm these findings.
Side Effects[edit | edit source]
The most common side effects of zometapine are similar to those of other atypical antipsychotics and include drowsiness, dizziness, and weight gain. Due to its anticholinergic properties, zometapine can also cause dry mouth, blurred vision, and constipation. In rare cases, zometapine may cause serious side effects such as neuroleptic malignant syndrome or tardive dyskinesia.
See Also[edit | edit source]
Dopamine receptor modulators | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Serotonin receptor modulators | ||||||
---|---|---|---|---|---|---|
|
Lua error in package.lua at line 80: module 'strict' not found.
Muscarinic acetylcholine receptor modulators | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
|
Lua error in package.lua at line 80: module 'strict' not found.
Lua error in package.lua at line 80: module 'strict' not found.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD